(pts) from VENTURE. Aim To assess DPL efficacy in TRAVERSE pts with severe OCS-dependent asthma by OCS dose at parent study baseline (PSBL; VENTURE).
Methods Pts from TRAVERSE were analyzed as DPL/DPL or placebo (PBO)/DPL group and stratified by OCS dose (≤10/>10mg/day at PSBL). % reduction in OCS dose and change in pre-BD FEV1 from PSBL at TRAVERSE Weeks (Wks) 0/96; % of pts achieving 0, <5, or <10mg/day OCS; AER during VENTURE and TRAVERSE were assessed.
Results 187 pts from TRAVERSE were analyzed. The daily-dose % reductions observed in VENTURE continued during TRAVERSE in DPL/DPL pts (Wk96: ≤10mg/day: −89%, >10mg/day: −83%) and PBO/DPL pts (Wk96: ≤10mg/day: −70%, >10mg/day: −76%). The % pts achieving 0, <5, or <10mg/day
OCS continued to improve throughout TRAVERSE regardless of OCS dose at PSBL. Also, AER was lower in TRAVERSE (range: 0.284–0.599) vs VENTURE (0.463–1.587), and pre-BD FEV1 continued to improve in all subgroups (Table).
Conclusion OCS dose reductions were sustained, and improvements in AER and lung function continued during TRAVERSE.
|Publication status||E-pub ahead of print - 30 Nov 2022|
|Event||European Respiratory Society (ERS) International Congress. - FIRA Barcelona Gran Via Congress Centre, Barcelona, Spain|
Duration: 4 Sept 2022 → 6 Sept 2022
|Conference||European Respiratory Society (ERS) International Congress.|
|Abbreviated title||ERS International Congress 2022|
|Period||4/09/22 → 6/09/22|